Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2016-04, Vol.18 (4), p.430-435
• Main Authors: Ard, J., Cannon, A., Lewis, C. E., Lofton, H., Vang Skjøth, T., Stevenin, B., Pi-Sunyer, X.
• Format: Article
• Language: English
• Subjects: Adult; Anti-Obesity Agents - administration & dosage; Anti-Obesity Agents - adverse effects; Anti-Obesity Agents - therapeutic use; Antidiabetics; antiobesity drug; Asian People; Black or African American; Black People; Body Mass Index; Body weight loss; Cardiovascular diseases; clinical trial; Combined Modality Therapy - adverse effects; Data processing; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - ethnology; Diet, Reducing - ethnology; Double-Blind Method; Evidence-based medicine; Exercise; Female; glucagon-like peptide-1 analogue; Glycated Hemoglobin - analysis; Humans; Hyperglycemia - ethnology; Hyperglycemia - prevention & control; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; liraglutide; Liraglutide - administration & dosage; Liraglutide - adverse effects; Liraglutide - therapeutic use; Male; Obesity; Obesity - complications; Obesity - drug therapy; Obesity - ethnology; Obesity - therapy; Overweight - complications; Overweight - drug therapy; Overweight - ethnology; Overweight - therapy; Prediabetic State - blood; Prediabetic State - complications; Prediabetic State - drug therapy; Prediabetic State - ethnology; Quality of Life; randomized trial; Research Letter; Research Letters; Safety; Statistical analysis; Weight control; Weight Loss - drug effects; Weight Loss - ethnology; White People
• ISSN: 1462-8902; 1463-1326; 1463-1326
• DOI: 10.1111/dom.12632

The efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to diet and exercise, was evaluated in racial subgroups. This post hoc analysis of pooled data from five double‐blind randomized, placebo‐controlled trials was conducted in 5325 adults with either a body mass index (BMI) ≥27 kg/m2 plus ≥1 comorbidity or a BMI ≥30 kg/m2. Statistical interaction tests evaluated possible treatment effect differences between racial subgroups: white (4496, 84.4%), black/African‐American (550, 10.3%), Asian (168, 3.2%) and other (111, 2.1%). Effects of liraglutide 3.0 mg on weight loss, associated metabolic effects and safety profile were generally consistent across racial subgroups. All achieved statistically significant mean weight loss at end‐of‐treatment with liraglutide 3.0 mg versus placebo: white 7.7% versus 2.3%, black/African‐American 6.3% versus 1.4%, Asian 6.3% versus 2.5%, other 7.3% versus 0.49%. Treatment effects on weight and cardiovascular risk markers generally showed no dependence on race (interaction test p > 0.05). Adverse events were similar across racial subgroups.